{"id":44731,"date":"2020-11-16T19:10:30","date_gmt":"2020-11-16T18:10:30","guid":{"rendered":"https:\/\/nationalwire.com.ng\/?p=44731"},"modified":"2020-11-16T19:10:41","modified_gmt":"2020-11-16T18:10:41","slug":"trials-show-new-covid-19-vaccine-94-5-effective-says-moderna","status":"publish","type":"post","link":"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/","title":{"rendered":"Trials Show New COVID-19 Vaccine 94.5% Effective, Says Moderna"},"content":{"rendered":"\n

\u200c<\/p>\n\n\n\n

US biotech firm Moderna on Monday announced its experimental vaccine against Covid-19 was almost 95 percent effective, marking a second major breakthrough in the quest to end the pandemic.<\/p>\n\n\n\n

Moderna released early results from a clinical trial with more than 30,000 participants, after American pharmaceutical company Pfizer and its German partner BioNTech last week said their vaccine was 90 percent effective.<\/p>\n\n\n\n

Both frontrunners are based on new technology that uses synthetic versions of molecules called \u201cmessenger RNA\u201d to hack into human cells, and effectively turn them into vaccine-making factories.\u201cThis positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease,\u201d said Moderna CEO Stephane Bancel.<\/p>\n\n\n\n

\u201cThe light at the end of the tunnel just got even brighter,\u201d tweeted Atul Gawande, a member of US President-elect Joe Biden\u2019s coronavirus advisory board and a surgeon at a Harvard-affiliated hospital.<\/p>\n\n\n\n

\u201cWe may now have multiple, very effective vaccines distributing widely in spring and summer,\u201d he added.<\/p>\n\n\n\n

Moderna plans to submit applications for emergency approval in the US and around the world within weeks, and says it expects to have approximately 20 million doses ready to ship in the US by the end of the year.<\/p>\n\n\n\n

It says it\u2019s on track to manufacture between 500 million to a billion doses globally in 2021.<\/p>\n\n\n\n

Global infections from Covid-19 have soared past 54 million with more than 1.3 million deaths since the virus emerged in China late last year.\u2013<\/strong><\/p>\n\n\n\n

 \u2018Tremendously exciting\u2019 \u2013<\/strong><\/p>\n\n\n\n

The Moderna vaccine, which was co-developed by the US National Institutes of Health, is given in two doses 28 days apart, and the preliminary results are based on the 95 of the 30,000 volunteers who fell ill with Covid-19.<\/p>\n\n\n\n

Of the 95, 90 had been in the trial\u2019s placebo group, and five in the group that received the drug, called mRNA-1273, translating to an efficacy rate of 94.5 percent.<\/p>\n\n\n\n

There were 11 people who fell severely ill, all of whom were in the placebo group.<\/p>\n\n\n\n

The US government has invested around $2 billion in funding for development, manufacturing, and potential delivery of the vaccine under its Operation Warp Speed.<\/p>\n\n\n\n

Most of the Moderna vaccine\u2019s side-effects were classed as mild or moderate.<\/p>\n\n\n\n

After the first dose, about three percent of people had injection site pain classed as severe.<\/p>

\r\n
Advertisement<\/div>\r\n\t\t\t\t\t\t\t<\/a>\r\n \r\n\t\t\t\t\t\t\t<\/div>\n\n\n\n

Among severe side-effects after the second dose, about 10 percent had fatigue, nine percent had muscle pain, five percent had joint pain or headaches, four percent had other pain and two percent had redness at the injection site.<\/p>\n\n\n\n

These adverse events were \u201cshort lived\u201d according to a statement.<\/p>\n\n\n\n

\u201cThis news from Moderna is tremendously exciting and considerably boosts optimism that we will have a choice of good vaccines in the next few months,\u201d said Peter Openshaw, a professor of experimental medicine at Imperial College London.<\/p>\n\n\n\n

Crucially, Moderna also announced that its vaccine can remain stable at standard refrigerator temperatures of 2 degrees Celsius to 8 degrees Celsius (36 degrees Fahrenheit to 46 degrees Fahrenheit) for 30 days.<\/p>\n\n\n\n

The company added it could be kept in long-term storage at standard freezer temperatures of -20 degrees Celsius (-4 degrees Fahrenheit) for up to six months.<\/p>\n\n\n\n

Pfizer\u2019s vaccine, on the other hand, needs to be stored in deep-freezer conditions of -70 degrees Celsius (-94 degrees Fahrenheit) which could complicate supply chain logistics, particularly in less developed countries.<\/p>\n\n\n\n

On the downside, Moderna\u2019s vaccine has about three times more genetic material per dose than its Pfizer counterpart, Zoltan Kis, a research associate at Imperial College\u2019s Future Vaccine Manufacturing Hub, said.<\/p>\n\n\n\n

This would raise production costs and make it harder to scale-up.<\/p>\n\n\n\n

\u2013 Questions remain \u2013<\/strong><\/p>\n\n\n\n

The promising results of both vaccines are seen as a validation for mRNA technology, which has never before been brought to regulatory approval.<\/p>\n\n\n\n

It works by providing human cells with the genetic instructions to make a surface protein of the coronavirus, which trains the immune system to recognize the real virus.<\/p>\n\n\n\n

Making a traditional vaccine is a longer process that normally involves developing a weakened form of a virus.<\/p>\n\n\n\n

It is not yet clear how long lasting the protection will be from either the Moderna or Pfizer vaccines, nor how well they work for the elderly, the age-group at highest risk from Covid-19.<\/p>\n\n\n\n

Another open question is whether they stop people who are exposed to the virus from transmitting it on to the other people, even though they may be themselves protected from the disease.<\/p>\n\n\n\n

AFP<\/p>\n","protected":false},"excerpt":{"rendered":"

\u200c US biotech firm Moderna on Monday announced its experimental vaccine against Covid-19 was almost 95 percent effective, marking a second major breakthrough in the quest to end the pandemic. Moderna released early results from a clinical trial with more than 30,000 participants, after American pharmaceutical company Pfizer and its German partner BioNTech last week …<\/p>\n","protected":false},"author":6,"featured_media":38644,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":""},"categories":[174,17],"tags":[6896],"coauthors":[2391],"class_list":["post-44731","post","type-post","status-publish","format-standard","has-post-thumbnail","","category-health","category-news","tag-covid-19"],"yoast_head":"\nTrials Show New COVID-19 Vaccine 94.5% Effective, Says Moderna - National Wire<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trials Show New COVID-19 Vaccine 94.5% Effective, Says Moderna - National Wire\" \/>\n<meta property=\"og:description\" content=\"\u200c US biotech firm Moderna on Monday announced its experimental vaccine against Covid-19 was almost 95 percent effective, marking a second major breakthrough in the quest to end the pandemic. Moderna released early results from a clinical trial with more than 30,000 participants, after American pharmaceutical company Pfizer and its German partner BioNTech last week …\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/\" \/>\n<meta property=\"og:site_name\" content=\"National Wire\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-16T18:10:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-11-16T18:10:41+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nationalwire.com.ng\/sub\/wp-content\/uploads\/2020\/02\/coronavirus-.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"696\" \/>\n\t<meta property=\"og:image:height\" content=\"410\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Friday Ekeoba\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebSite\",\"@id\":\"https:\/\/nationalwire.com.ng\/sub\/#website\",\"url\":\"https:\/\/nationalwire.com.ng\/sub\/\",\"name\":\"National Wire\",\"description\":\"About Nigerians, Nigerian Business and Other Stories\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/nationalwire.com.ng\/sub\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/#primaryimage\",\"url\":\"https:\/\/nationalwire.com.ng\/sub\/wp-content\/uploads\/2020\/02\/coronavirus-.jpg\",\"contentUrl\":\"https:\/\/nationalwire.com.ng\/sub\/wp-content\/uploads\/2020\/02\/coronavirus-.jpg\",\"width\":696,\"height\":410,\"caption\":\"COVID-19\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/#webpage\",\"url\":\"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/\",\"name\":\"Trials Show New COVID-19 Vaccine 94.5% Effective, Says Moderna - National Wire\",\"isPartOf\":{\"@id\":\"https:\/\/nationalwire.com.ng\/sub\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/#primaryimage\"},\"datePublished\":\"2020-11-16T18:10:30+00:00\",\"dateModified\":\"2020-11-16T18:10:41+00:00\",\"author\":{\"@id\":\"https:\/\/nationalwire.com.ng\/sub\/#\/schema\/person\/e2ab303e561d755b325fc9cea3854927\"},\"breadcrumb\":{\"@id\":\"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/nationalwire.com.ng\/sub\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trials Show New COVID-19 Vaccine 94.5% Effective, Says Moderna\"}]},{\"@type\":\"Person\",\"@id\":\"https:\/\/nationalwire.com.ng\/sub\/#\/schema\/person\/e2ab303e561d755b325fc9cea3854927\",\"name\":\"Friday Ekeoba\",\"url\":\"https:\/\/nationalwire.com.ng\/sub\/author\/friday\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trials Show New COVID-19 Vaccine 94.5% Effective, Says Moderna - National Wire","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/","og_locale":"en_US","og_type":"article","og_title":"Trials Show New COVID-19 Vaccine 94.5% Effective, Says Moderna - National Wire","og_description":"\u200c US biotech firm Moderna on Monday announced its experimental vaccine against Covid-19 was almost 95 percent effective, marking a second major breakthrough in the quest to end the pandemic. Moderna released early results from a clinical trial with more than 30,000 participants, after American pharmaceutical company Pfizer and its German partner BioNTech last week …","og_url":"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/","og_site_name":"National Wire","article_published_time":"2020-11-16T18:10:30+00:00","article_modified_time":"2020-11-16T18:10:41+00:00","og_image":[{"width":696,"height":410,"url":"https:\/\/nationalwire.com.ng\/sub\/wp-content\/uploads\/2020\/02\/coronavirus-.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Written by":"Friday Ekeoba","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebSite","@id":"https:\/\/nationalwire.com.ng\/sub\/#website","url":"https:\/\/nationalwire.com.ng\/sub\/","name":"National Wire","description":"About Nigerians, Nigerian Business and Other Stories","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nationalwire.com.ng\/sub\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/#primaryimage","url":"https:\/\/nationalwire.com.ng\/sub\/wp-content\/uploads\/2020\/02\/coronavirus-.jpg","contentUrl":"https:\/\/nationalwire.com.ng\/sub\/wp-content\/uploads\/2020\/02\/coronavirus-.jpg","width":696,"height":410,"caption":"COVID-19"},{"@type":"WebPage","@id":"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/#webpage","url":"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/","name":"Trials Show New COVID-19 Vaccine 94.5% Effective, Says Moderna - National Wire","isPartOf":{"@id":"https:\/\/nationalwire.com.ng\/sub\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/#primaryimage"},"datePublished":"2020-11-16T18:10:30+00:00","dateModified":"2020-11-16T18:10:41+00:00","author":{"@id":"https:\/\/nationalwire.com.ng\/sub\/#\/schema\/person\/e2ab303e561d755b325fc9cea3854927"},"breadcrumb":{"@id":"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nationalwire.com.ng\/sub\/trials-show-new-covid-19-vaccine-94-5-effective-says-moderna\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nationalwire.com.ng\/sub\/"},{"@type":"ListItem","position":2,"name":"Trials Show New COVID-19 Vaccine 94.5% Effective, Says Moderna"}]},{"@type":"Person","@id":"https:\/\/nationalwire.com.ng\/sub\/#\/schema\/person\/e2ab303e561d755b325fc9cea3854927","name":"Friday Ekeoba","url":"https:\/\/nationalwire.com.ng\/sub\/author\/friday\/"}]}},"_links":{"self":[{"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/posts\/44731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/comments?post=44731"}],"version-history":[{"count":1,"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/posts\/44731\/revisions"}],"predecessor-version":[{"id":44735,"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/posts\/44731\/revisions\/44735"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/media\/38644"}],"wp:attachment":[{"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/media?parent=44731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/categories?post=44731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/tags?post=44731"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/nationalwire.com.ng\/sub\/wp-json\/wp\/v2\/coauthors?post=44731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}